Therapeutic strategies for Alzheimer's disease in clinical trials

Pharmacological Reports

Volumn 68, Issue 1, 2016, Pages 127-138

  Godyń, Justyna ^a   Jończyk, Jakub ^a   Panek, Dawid ^a   Malawska, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Alzheimer's disease; Anti amyloid immunotherapy; Anti tau immunotherapy; Clinical trials; Secretase inhibitors

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ABT 288; ALZHEIMER DISEASE VACCINE; AMARANTH; AVAGACESTAT; AZD 3293; AZELIRAGON; BAPINEUZUMAB; BEGACESTAT; BETA SECRETASE INHIBITOR; CRENEZUMAB; DONEPEZIL; ENCENICLINE; EPOTHILONE D; GANTENERUMAB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GSK 239512; IDALOPIRDINE; IMMUNOGLOBULIN; INSULIN; LIRAGLUTIDE; NILVADIPINE; PIOGLITAZONE; SEMAGACESTAT; SOLANEZUMAB; THALIDOMIDE; TIDEGLUSIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANUTIDE CRIDIFICAR; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; SECRETASE; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DRUG REPOSITIONING; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROTRANSMISSION; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; TAU PROTEINS;

EID: 84953868005     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2015.07.006     Document Type: Review

References (103)

1. R. Anand, K.D. Gill, and A.A. Mahdi Therapeutics of Alzheimer's disease: past, present and future Neuropharmacology 76 Part A 2014 27 50
2. C.P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, and et al. Global prevalence of dementia: a Delphi consensus study Lancet 366 9503 2005 2112 2117
3. A. Wimo, L. Jonsson, J. Bond, M. Prince, and B. Winblad Alzheimer Disease international. The worldwide economic impact of dementia 2010 Alzheimers Dement 9 1 2013 1 11 e3
4. C. Reitz, C. Brayne, and R. Mayeux Epidemiology of Alzheimer disease Nat Rev Neurol 7 3 2011 137 152
5. E. Bagyinszky, Y.C. Youn, S.S. An, and S. Kim The genetics of Alzheimer's disease Clin Interv Aging 9 2014 535 551
6. R.J. Castellani, and G. Perry The complexities of the pathology-pathogenesis relationship in Alzheimer disease Biochem Pharmacol 88 4 2014 671 676
7. J. Hardy, N. Bogdanovic, B. Winblad, E. Portelius, N. Andreasen, A. Cedazo-Minguez, and et al. Pathways to Alzheimer's disease J Intern Med 275 3 2014 296 303
8. P. Davies, and A.J. Maloney Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 2 8000 1976 1403
9. D.M. Robinson, and G.M. Keating Memantine: a review of its use in Alzheimer's disease Drugs 66 11 2006 1515 1534
10. L. Ghezzi, E. Scarpini, and D. Galimberti Disease-modifying drugs in Alzheimer's disease Drug Des Devel Ther 7 2013 1471 1478
11. S.H. Han, and I. Mook-Jung Diverse molecular targets for therapeutic strategies in Alzheimer's disease J Kor Med Sci 29 7 2014 893 902
12. J. Lundkvist, M.M. Halldin, J. Sandin, G. Nordvall, P. Forsell, S. Svensson, and et al. The battle of Alzheimer's Disease - the beginning of the future unleashing the potential of academic discoveries Front Pharmacol 5 2014 102
13. L.S. Schneider, F. Mangialasche, N. Andreasen, H. Feldman, E. Giacobini, R. Jones, and et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 J Intern Med 275 3 2014 251 283
14. H. Zheng, M. Fridkin, and M. Youdim New approaches to treating Alzheimer's disease Perspect Med Chem 7 2015 1 8
15. T. Wisniewski, and F. Goni Immunotherapy for Alzheimer's disease Biochem Pharmacol 88 4 2014 499 507
16. Q. Jia, Y. Deng, and H. Qing Potential therapeutic strategies for Alzheimer's disease targeting or beyond beta-amyloid: insights from clinical trials Biomed Res Int 2014 2014 837157
17. A. Kumar, and A. Singh Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update Pharmacol Rep 67 2 2015 195 203
18. F. Saez-Orellana, P.A. Godoy, C.Y. Bastidas, T. Silva-Grecchi, L. Guzman, L.G. Aguayo, and et al. ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of beta-amyloid peptide in hippocampal neurons Neuropharmacology 2015 10.1016/j.neuropharm.2015.04.005
19. A. Serrano-Pozo, M.P. Frosch, E. Masliah, and B.T. Hyman Neuropathological alterations in Alzheimer disease Cold Spring Harb Perspect Med 1 1 2011 a006189
20. T.E. Golde The pathogenesis of Alzheimer's disease and the role of Abeta42 CNS Spectr 12 1 (Suppl. 1) 2007 4 6
21. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, N.C. Fox, and et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 9 2012 795 804
22. D. Schenk, G.S. Basi, and M.N. Pangalos Treatment strategies targeting amyloid beta-protein Cold Spring Harb Perspect Med 2 9 2012 a006387
23. L. Lannfelt, N.R. Relkin, and E.R. Siemers Amyloid-ss-directed immunotherapy for Alzheimer's disease J Intern Med 275 3 2014 284 295
24. C. Paquet, J. Amin, F. Mouton-Liger, M. Nasser, S. Love, F. Gray, and et al. Effect of active Abeta immunotherapy on neurons in human Alzheimer's disease J Pathol 235 5 2015 721 730
25. F. Panza, G. Logroscino, B.P. Imbimbo, and V. Solfrizzi Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr Opin Psychiatry 27 2 2014 128 137
26. F. Panza, V. Solfrizzi, B.P. Imbimbo, R. Tortelli, A. Santamato, and G. Logroscino Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward Expert Rev Clin Immunol 10 3 2014 405 419
27. B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, T. Dumortier, and et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol 11 7 2012 597 604
28. https://clinicaltrials.gov
29. H. Arai, H. Suzuki, T. Yoshiyama, K. Lobello, Y. Peng, E. Liu, and et al. Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: a phase IIa, multicenter, randomized, adjuvant and placebo clinical trial Alzheimer's Dement 9 4 2013 282
30. R.S. Doody, R.G. Thomas, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, and et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 4 2014 311 321
31. T. Leyhe, N. Andreasen, M. Simeoni, A. Reich, C.A. von Arnim, X. Tong, and et al. Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study Alzheimers Res Ther 6 2 2014 19
32. N. Relkin Clinical trials of intravenous immunoglobulin for Alzheimer's disease J Clin Immunol 34 Suppl 1 2014 74 79
33. T.E. Golde, E.H. Koo, K.M. Felsenstein, B.A. Osborne, and L. Miele gamma-Secretase inhibitors and modulators Biochim Biophys Acta 1828 12 2013 2898 2907
34. J.A. Mikulca, V. Nguyen, D.A. Gajdosik, S.G. Teklu, E.A. Giunta, E.A. Lessa, and et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches J Clin Pharm Ther 39 1 2014 25 37
35. A. Haapasalo, and D.M. Kovacs The many substrates of presenilin/gamma-secretase J Alzheimers Dis 25 1 2011 3 28
36. A.E. Roher, C.L. Maarouf, T.A. Kokjohn, C.M. Whiteside, W.M. Kalback, G. Serrano, and et al. Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the gamma-secretase inhibitor semagacestat Am J Neurodegener Dis 3 3 2014 115 133
37. R.S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, and et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease N Engl J Med 369 4 2013 341 350
38. S. Artavanis-Tsakonas, M.D. Rand, and R.J. Lake Notch signaling: cell fate control and signal integration in development Science 284 5415 1999 770 776
39. C.K. Hsu, C.C. Hsu, J.Y. Lee, Y.M. Kuo, and M.C. Pai Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor J Am Acad Dermatol 68 2 2013 e46 e48
40. B.P. Imbimbo Therapeutic potential of gamma-secretase inhibitors and modulators Curr Top Med Chem 8 1 2008 54 61
41. M. Willem, A.N. Garratt, B. Novak, M. Citron, S. Kaufmann, A. Rittger, and et al. Control of peripheral nerve myelination by the beta-secretase BACE1 Science 314 5799 2006 664 666
42. S. Musardo, E. Marcello, F. Gardoni, and M. Di Luca ADAM10 in synaptic physiology and pathology Neurodegener Dis 13 2-3 2014 72 74
43. R. Yan, and R. Vassar Targeting the beta secretase BACE1 for Alzheimer's disease therapy Lancet Neurol 13 3 2014 319 329
44. R. Vassar BACE1 inhibitor drugs in clinical trials for Alzheimer's disease Alzheimers Res Ther 6 9 2014 89-014-0089-7
45. D.K. Lahiri, B. Maloney, J.M. Long, and N.H. Greig Lessons from a BACE1 inhibitor trial: off-site but not off base Alzheimers Dement 10 5 SUPPL 2014 S411 S419
46. P.H. Kuhn, K. Koroniak, S. Hogl, A. Colombo, U. Zeitschel, M. Willem, and et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons EMBO J 31 14 2012 3157 3168
47. T. Jonsson, J.K. Atwal, S. Steinberg, J. Snaedal, P.V. Jonsson, S. Bjornsson, and et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline Nature 488 7409 2012 96 99
48. D.M. Holtzman, J.C. Morris, and A.M. Goate Alzheimer's disease: the challenge of the second century Sci Transl Med 3 77 2011 77sr1
49. R.M. Nisbet, J.C. Polanco, L.M. Ittner, and J. Gotz Tau aggregation and its interplay with amyloid-beta Acta Neuropathol 129 2 2015 207 220
50. R.A. Sperling, D.M. Rentz, K.A. Johnson, J. Karlawish, M. Donohue, D.P. Salmon, and et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6 228 2014 228fs13
51. A.D. Roses, A.M. Saunders, M.W. Lutz, N. Zhang, A.R. Hariri, K.E. Asin, and et al. New applications of disease genetics and pharmacogenetics to drug development Curr Opin Pharmacol 14 2014 81 89
52. S.M. Mills, J. Mallmann, A.M. Santacruz, A. Fuqua, M. Carril, P.S. Aisen, and et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial Rev Neurol (Paris) 169 10 2013 737 743
53. J. Hardy, and D. Allsop Amyloid deposition as the central event in the aetiology of Alzheimer's disease Trends Pharmacol Sci 12 10 1991 383 388
54. M.L. Garcia, and D.W. Cleveland Going new places using an old MAP: tau, microtubules and human neurodegenerative disease Curr Opin Cell Biol 13 1 2001 41 48
55. C.M. Wischik, C.R. Harrington, and J.M. Storey Tau-aggregation inhibitor therapy for Alzheimer's disease Biochem Pharmacol 88 4 2014 529 539
56. F. Gruninger Invited review: drug development for tauopathies Neuropathol Appl Neurobiol 41 1 2015 81 96
57. B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. McDonald-Jones, J. Bruce, and et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model Proc Natl Acad Sci U S A 102 1 2005 227 231
58. M. Novak Tau vaccine: active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy Alzheimer's Dement 5 4 2009 93
59. C. Theunis, N. Crespo-Biel, V. Gafner, M. Pihlgren, M.P. Lopez-Deber, P. Reis, and et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy PLOS ONE 8 8 2013 72301
60. T. del Ser, K.C. Steinwachs, H.J. Gertz, M.V. Andres, B. Gomez-Carrillo, M. Medina, and et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study J Alzheimers Dis 33 1 2013 205 215
61. L. Sereno, M. Coma, M. Rodriguez, P. Sanchez-Ferrer, M.B. Sanchez, I. Gich, and et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo Neurobiol Dis 35 3 2009 359 367
62. T. del Ser, S. Lovestone, M. Boada-Rovira, B. Dubois, M. Hull, J. Rinne, and et al. A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (argo trial) Alzheimer's Dement 9 4 2013 P689 P690
63. S. Lovestone, M. Boada, B. Dubois, M. Hull, J.O. Rinne, H.J. Huppertz, and et al. A phase II trial of tideglusib in Alzheimer's disease J Alzheimers Dis 45 1 2015 75 88
64. Y. Yang, D. Ma, Y. Wang, T. Jiang, S. Hu, M. Zhang, and et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes J Alzheimers Dis 33 2 2013 329 338
65. A. Claxton, L.D. Baker, C.W. Wilkinson, E.H. Trittschuh, D. Chapman, G.S. Watson, and et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease J Alzheimers Dis 35 4 2013 789 797
66. M.A. Reger, G.S. Watson, P.S. Green, L.D. Baker, B. Cholerton, M.A. Fishel, and et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults J Alzheimers Dis 13 3 2008 323 331
67. M.A. Reger, G.S. Watson, P.S. Green, C.W. Wilkinson, L.D. Baker, B. Cholerton, and et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD Neurology 70 6 2008 440 448
68. B. Marcos, M. Cabero, M. Solas, B. Aisa, and M.J. Ramirez Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects Int J Neuropsychopharmacol 13 6 2010 775 784
69. D. Marazziti, G. Rutigliano, M. Catena-DelL'Osso, S. Baroni, and L. Dell'Osso The 5-HT6 receptor antagonism approach in Alzheimer's disease Drugs Future 39 2 2014 133 140
70. D. Wilkinson, K. Windfeld, and E. Colding-Jorgensen Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 13 11 2014 1092 1099
71. L.S. Schneider Idalopirdine for Alzheimer's disease: written in the stars Lancet Neurol 13 11 2014 1063 1065
72. B. Marcos, T.T. Chuang, F.J. Gil-Bea, and M.J. Ramirez Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat Br J Pharmacol 155 3 2008 434 440
73. D. Wilkinson, E. Colding-Jorgensen, and K. Windfeld A clinical phase II study of LU AE58054 added to stable donepezil treatment in patients with moderate Alzheimer's disease Alzheimer's Dement 9 4 2013 529
74. G. Maher-Edwards, M. Zvartau-Hind, A.J. Hunter, M. Gold, G. Hopton, G. Jacobs, and et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease Curr Alzheimer Res 7 5 2010 374 385
75. M. Motawaj, A. Burban, E. Davenas, F. Gbahou, R. Faucard, S. Morisset, and et al. The histaminergic system: a target for innovative treatments of cognitive deficits Therapie 65 5 2010 415 422
76. T.A. Esbenshade, K.E. Browman, R.S. Bitner, M. Strakhova, M.D. Cowart, and J.D. Brioni The histamine H3 receptor: an attractive target for the treatment of cognitive disorders Br J Pharmacol 154 6 2008 1166 1181
77. T.A. Esbenshade, K.E. Browman, T.R. Miller, K.M. Krueger, V. Komater-Roderwald, M. Zhang, and et al. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist J Pharmacol Exp Ther 343 1 2012 233 245
78. A.A. Othman, G. Haig, H. Florian, C. Locke, L. Gertsik, and S. Dutta The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers Br J Clin Pharmacol 77 6 2014 965 974
79. G.M. Haig, Y. Pritchett, A. Meier, A.A. Othman, C. Hall, L.M. Gault, and et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia J Alzheimers Dis 42 3 2014 959 971
80. R.A. Grove, C.M. Harrington, A. Mahler, I. Beresford, P. Maruff, M.T. Lowy, and et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease Curr Alzheimer Res 11 1 2014 47 58
81. A.H. Burstein, I. Grimes, D.R. Galasko, P.S. Aisen, M. Sabbagh, and A.M. Mjalli Effect of TTP488 in patients with mild to moderate Alzheimer's disease BMC Neurol 14 2014 12-2377-14-12
82. J. Prickaerts, N.P. van Goethem, R. Chesworth, G. Shapiro, F.G. Boess, C. Methfessel, and et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors Neuropharmacology 2 2012 1099 1110
83. E. Tarkowski, N. Andreasen, A. Tarkowski, and K. Blennow Intrathecal inflammation precedes development of Alzheimer's disease Neurol Neurosurg Psychiatry 74 9 2003 1200 1205
84. S.P. Gabbita, M.K. Srivastava, P. Eslami, M.F. Johnson, N.K. Kobritz, D. Tweedie, and et al. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease J Neuroinflammation 9 2012 99-2094-9-99
85. S.L. Walker, M.F. Waters, and D.N. Lockwood The role of thalidomide in the management of erythema nodosum leprosum Lepr Rev 78 3 2007 197 215
86. P. Moreau, M. Attal, and T. Facon Frontline therapy of multiple myeloma Blood 125 20 2015 3076 3084
87. N. Kumar, U. Sharma, C. Singh, and B. Singh Thalidomide chemistry, therapeutic potential and oxidative stress induced teratogenicity Curr Top Med Chem 12 13 2012 1436 1455
88. N.H. Greig, T. Giordano, X. Zhu, Q.S. Yu, T.A. Perry, H.W. Holloway, and et al. Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases Acta Neurobiol Exp (Wars) 64 1 2004 1 9
89. A.R. Cole, A. Astell, C. Green, and C. Sutherland Molecular connexions between dementia and diabetes Neurosci Biobehav Rev 31 7 2007 1046 1063
90. M.J. During, L. Cao, D.S. Zuzga, J.S. Francis, H.L. Fitzsimons, X. Jiao, and et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection Nat Med 9 9 2003 1173 1179
91. T. Abbas, E. Faivre, and C. Holscher Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease Behav Brain Res 205 1 2009 265 271
92. L. Egefjord, M. Gejl, A. Moller, H. Braendgaard, H. Gottrup, O. Antropova, and et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial Dan Med J 59 10 2012 A4519
93. B. Lawlor, S. Kennelly, S. O'Dwyer, F. Cregg, C. Walsh, R. Coen, and et al. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease BMJ Open 4 10 2014 e006364-2014-006364
94. A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, and et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease Neurology 43 8 1993 1467 1472
95. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, and et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 5123 1993 921 923
96. E. Lai, J. Riley, I. Purvis, and A. Roses A 4-Mb high-density single nucleotide polymorphism-based map around human APOE Genomics 54 1 1998 31 38
97. R.L. Strausberg, E.A. Feingold, L.H. Grouse, J.G. Derge, R.D. Klausner, F.S. Collins, and et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences Proc Natl Acad Sci U S A 99 26 2002 16899 16903
98. H.K. Chen, Z. Liu, A. Meyer-Franke, J. Brodbeck, R.D. Miranda, J.G. McGuire, and et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons J Biol Chem 287 8 2012 5253 5266
99. D.G. Crenshaw, W.K. Gottschalk, M.W. Lutz, I. Grossman, A.M. Saunders, J.R. Burke, and et al. Using genetics to enable studies on the prevention of Alzheimer's disease Clin Pharmacol Ther 93 February 2 2013 177 185
100. C. Linnertz, A.M. Saunders, M.W. Lutz, D.M. Crenshaw, I. Grossman, D.K. Burns, and et al. Characterization of the poly-T variant in the TOMM40 gene in diverse populations PLoS One 7 2 2012 e30994
101. N. Ayutyanont, J.B. Langbaum, S.B. Hendrix, K. Chen, A.S. Fleisher, M. Friesenhahn, and et al. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers J Clin Psychiatry 75 6 2014 652 660
102. J.L. Cummings, T. Morstorf, and K. Zhong Alzheimer's disease drug-development pipeline: few candidates, frequent failures Alzheimers Res Ther 6 4 2014 37
103. N. Guzior, A. Wieckowska, D. Panek, and B. Malawska Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease Curr Med Chem 22 3 2015 373 404